Ken Fisher's HALO Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 467,852 shares of Halozyme Therapeutics, Inc. (HALO) worth $31.49 M, representing 0.01% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 47 quarters.
Based on 13F filings since 2013, Ken Fisher has maintained a long-term strategic position in HALO, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2018, adding 418,581 shares. Largest reduction occurred in Q3 2022, reducing 326,289 shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's Halozyme Therapeutics (HALO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Halozyme Therapeutics (HALO) Trades by Ken Fisher
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +56,960 | Add 13.86% | 467,852 | $67.30 |
| Q3 2025 | +29,147 | Add 7.64% | 410,892 | $73.34 |
| Q2 2025 | -35,771 | Reduce 8.57% | 381,745 | $52.02 |
| Q1 2025 | +2,797 | Add 0.67% | 417,516 | $63.81 |
| Q4 2024 | +90,714 | Add 28.00% | 414,719 | $47.81 |
| Q3 2024 | +20,721 | Add 6.83% | 324,005 | $57.24 |
| Q2 2024 | +26,212 | Add 9.46% | 303,284 | $52.36 |
| Q1 2024 | +170 | Add 0.06% | 277,072 | $40.68 |
| Q4 2023 | +1,667 | Add 0.61% | 276,902 | $36.96 |
| Q3 2023 | -154,084 | Reduce 35.89% | 275,235 | $38.20 |
| Q2 2023 | -2,990 | Reduce 0.69% | 429,319 | $36.07 |
| Q1 2023 | -3,608 | Reduce 0.83% | 432,309 | $38.19 |
| Q4 2022 | -253,083 | Reduce 36.73% | 435,917 | $56.90 |
| Q3 2022 | -326,289 | Reduce 32.14% | 689,000 | $39.54 |
| Q2 2022 | +73,775 | Add 7.84% | 1.02 M | $44.00 |
| Q1 2022 | -1,216 | Reduce 0.13% | 941,514 | $39.88 |
| Q4 2021 | -62,708 | Reduce 6.24% | 942,730 | $40.21 |
| Q3 2021 | +81,724 | Add 8.85% | 1.01 M | $40.68 |
| Q2 2021 | +25,637 | Add 2.85% | 923,714 | $45.41 |
| Q1 2021 | -12,638 | Reduce 1.39% | 898,077 | $41.69 |
| Q4 2020 | -43,442 | Reduce 4.55% | 910,715 | $42.71 |
| Q3 2020 | -102,514 | Reduce 9.70% | 954,157 | $26.28 |
| Q2 2020 | -38,000 | Reduce 3.47% | 1.06 M | $26.81 |
| Q1 2020 | -87,992 | Reduce 7.44% | 1.09 M | $17.99 |
| Q4 2019 | +12,747 | Add 1.09% | 1.18 M | $17.73 |
| Q3 2019 | +6,756 | Add 0.58% | 1.17 M | $15.51 |
| Q2 2019 | +221,470 | Add 23.52% | 1.16 M | $17.18 |
| Q1 2019 | +75,771 | Add 8.75% | 941,690 | $16.10 |
| Q4 2018 | +418,581 | Add 93.57% | 865,919 | $14.63 |
| Q3 2018 | -6,314 | Reduce 1.39% | 447,338 | $18.17 |
| Q2 2018 | -44,362 | Reduce 8.91% | 453,652 | $16.87 |
| Q1 2018 | -62,359 | Reduce 11.13% | 498,014 | $19.59 |
| Q4 2017 | -22,848 | Reduce 3.92% | 560,373 | $20.26 |
| Q3 2017 | -30,800 | Reduce 5.02% | 583,221 | $17.37 |
| Q2 2017 | -2,490 | Reduce 0.40% | 614,021 | $12.82 |
| Q1 2017 | -46,300 | Reduce 6.99% | 616,511 | $12.96 |
| Q4 2016 | -62,200 | Reduce 8.58% | 662,811 | $9.88 |
| Q2 2016 | +17,231 | Add 2.43% | 725,011 | $9.08 |
| Q3 2015 | -33,175 | Reduce 4.48% | 707,780 | $13.43 |
| Q2 2015 | -21,825 | Reduce 2.86% | 740,955 | $22.58 |
| Q3 2014 | -28,980 | Reduce 3.66% | 762,780 | $9.10 |
| Q2 2014 | +791,760 | New Buy | 791,760 | $9.88 |
Ken Fisher's Halozyme Therapeutics Investment FAQs
Ken Fisher first purchased Halozyme Therapeutics, Inc. (HALO) in Q2 2014, acquiring 791,760 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held Halozyme Therapeutics, Inc. (HALO) for 47 quarters since Q2 2014.
Ken Fisher's largest addition to Halozyme Therapeutics, Inc. (HALO) was in Q2 2014, adding 791,760 shares worth $7.82 M.
According to the latest 13F filing for Q4 2025, Ken Fisher's firm, Fisher Asset Management, LLC, owns 467,852 shares of Halozyme Therapeutics, Inc. (HALO), valued at approximately $31.49 M.
As of the Q4 2025 filing, Halozyme Therapeutics, Inc. (HALO) represents approximately 0.01% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.
Ken Fisher's peak holding in Halozyme Therapeutics, Inc. (HALO) was 1,182,663 shares, as reported at the end of Q4 2019.